albendazole
jurox pty limited - albendazole - unknown - albendazole carbamate-benzimidazole active 0.0 - active constituent
albendazole tablet, film coated
dr.reddys laboratories inc - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole tablets are contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tablets. risk summary based on findings from animal reproduction studies, albendazole may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. i
albendazole tablet
pharma packaging solutions, llc dba tjoapack llc - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium. albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus. albendazole tablets are contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tablets. risk summary based on findings from animal reproduction studies, albendazole tablets may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1 st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse mater
albenza- albendazole tablet, film coated
central texas community health centers - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole 200 mg - albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albenza is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albenza is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albenza. pregnancy category c. there are no adequate and well-controlled studies of albenza administration in pregnant women. albenza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. albenza should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. obtain pregnancy test prior to prescribing albenza to women of reproductive potential. advise women of reproductive potential to use effective birth control for the duration of albenza therapy and for
albenza- albendazole tablet, film coated
department of state health services, pharmacy branch - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole 200 mg - albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albenza is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albenza is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albenza. pregnancy category c. there are no adequate and well-controlled studies of albenza administration in pregnant women. albenza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. albenza should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. obtain pregnancy test prior to prescribing albenza to women of reproductive potential. advise women of reproductive potential to use effective birth control for the duration of albenza therapy and for
albenza- albendazole tablet, film coated
amedra pharmaceuticals llc - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole 200 mg - albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albenza is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albenza is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albenza. pregnancy category c. there are no adequate and well-controlled studies of albenza administration in pregnant women. albenza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. albenza should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. obtain pregnancy test prior to prescribing albenza to women of reproductive potential. advise women of reproductive potential to use effective birth control for the duration of albenza therapy and for
x - albendazole powder
ax pharmaceutical corp - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole 247.5 g in 250 g
albendazole tablets chewable
arpimed llc - albendazole - tablets chewable - 400mg
eskazole albendazole 400mg chewable tablet
aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: povidone; sodium lauryl sulfate; saccharin sodium; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; maize starch; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.
eskazole albendazole 400mg chewable tablet
aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: saccharin sodium; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; povidone; magnesium stearate; maize starch; lactose monohydrate; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.